Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells

Cancer Research

Volumn 69, Issue 23, 2009, Pages 8853-8861

  Chen, Lu ^a   Mayer, Julie Ann ^a   Krisko, Tibor I ^a   Speers, Corey W ^a   Wang, Tao ^a   Hilsenbeck, Susan G ^a   Brown, Powel H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 DELTA; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER CELL CULTURE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL STRESS; CELL SURVIVAL; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; ENZYME INHIBITION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WILD TYPE;

BREAST NEOPLASMS; CELL ADHESION; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; GENE SILENCING; HUMANS; IMIDAZOLES; MAP KINASE SIGNALING SYSTEM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOPROTEIN PHOSPHATASES; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTORS, ESTROGEN; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 71549116718     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1636     Document Type: Article

References (50)

1. Society AC. Breast Cancer Facts and Figures 2009. Atlanta: American Cancer Society; 2009.
2. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388 (Pubitemid 28439961)
3. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-2197 (Pubitemid 29275701)
4. American CS. Estimated new cancer cases and deaths by gender. Atlanta: American Cancer Society; 2002.
5. Tan AR, Swain SM. Adjuvant chemotherapy for breast cancer: an update. Semin Oncol 2001;28:359-376 (Pubitemid 32762081)
6. Cano E, Mahadevan LC. Parallel signal processing among mammalian MAPKs. Trends Biochem Sci 1995;20:117-122
7. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal 2000;12:1-13. (Pubitemid 30017963)
8. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997;9:180-186
9. Han J, Lee JD, Tobias PS, Ulevitch RJ. Endotoxin induces rapid protein tyrosine phosphorylation in 70Z/3 cells expressing CD14. J Biol Chem 1993;268:25009-25014 (Pubitemid 23335522)
10. Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994;265:808-811 (Pubitemid 24266145)
11. Jiang Y, Chen C, Li Z, et al. Characterization of the structure and function of a new mitogen-activated protein kinase (p38β). J Biol Chem 1996;271:17920-17926 (Pubitemid 26250772)
12. Lechner C, Zahalka MA, Giot JF, Moller NP, Ullrich A. ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast differentiation. Proc Natl Acad Sci U S A 1996;93:4355-4359 (Pubitemid 26144291)
13. Li Z, Jiang Y, Ulevitch RJ, Han J. The primary structure of p38 γ: a new member of p38 group of MAP kinases. Biochem Biophys Res Commun 1996;228:334-340
14. Mertens S, Craxton M, Goedert M. SAP kinase-3, a new member of the family of mammalian stress-activated protein kinases. FEBS Lett 1996;383:273-276 (Pubitemid 26104075)
15. Kumar S, McDonnell PC, Gum RJ, Hand AT, Lee JC, Young PR. Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophys Res Commun 1997;235:533-538 (Pubitemid 27326515)
16. Wang XS, Diener K, Manthey CL, et al. Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase. J Biol Chem 1997;272:23668-23674 (Pubitemid 27410940)
17. Enslen H, Raingeaud J, Davis RJ. Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. J Biol Chem 1998;273:1741-1748 (Pubitemid 28133705)
18. Knebel A, Morrice N, Cohen P. A novel method to identify protein kinase substrates: eEF2 kinase is phosphorylated and inhibited by SAPK4/p38 . EMBO J 2001;20:4360-4369 (Pubitemid 32772030)
19. Salh B, Marotta A, Wagey R, Sayed M, Pelech S. Dysregulation of phosphatidylinositol 3-kinase and downstream effectors in human breast cancer. Int J Cancer 2002;98:148-154 (Pubitemid 34113432)
20. Esteva FJ, Sahin AA, Smith TL, et al. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph nodepositive breast carcinoma. Cancer 2004;100:499-506.
21. Gutierrez MC, Detre S, Johnston S, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005;23:2469-2476 (Pubitemid 47050837)
22. Davidson B, Konstantinovsky S, Kleinberg L, et al. The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol 2006.
23. Liu Y, Lu C, Shen Q, Munoz-Medellin D, Kim H, Brown PH. AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity. Oncogene 2004;23:8238-8246 (Pubitemid 39531835)
24. Kim HT, Kong G, Denardo D, et al. Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res 2006;66:12009-12018 (Pubitemid 46094215)
25. Ashwell JD. The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat Rev Immunol 2006;6:532-540 (Pubitemid 43980525)
26. Sudo T, Kawai K, Matsuzaki H, Osada H. p38 mitogen-activated protein kinase plays a key role in regulating MAPKAPK2 expression. Biochem Biophys Res Commun 2005;337:415.
27. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-527 (Pubitemid 44854747)
28. Wasielewski M, Elstrodt F, Klijn JG, Berns EM, Schutte M. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines. Breast Cancer Res Treat 2006;99:97-101. (Pubitemid 44168609)
29. Concin N, Zeillinger C, Tong D, et al. Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines. Breast Cancer Res Treat 2003;79:37-46. (Pubitemid 36561041)
30. Sugden PH, Clerk A. Oxidative stress and growth-regulating intracellular signaling pathways in cardiac myocytes. Antioxid Redox Signal 2006;8:2111-2124 (Pubitemid 46489635)
31. Sumbayev VV, Yasinska IM. Role of MAP kinase-dependent apoptotic pathway in innate immune responses and viral infection. Scand J Immunol 2006;63:391-400.
32. Baines CP, Molkentin JD. STRESS signaling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol 2005;38:47-62.
33. Hendrickx N, Volanti C, Moens U, et al. Up-regulation of cyclooxygenase-2 and apoptosis resistance by p38 MAPK in hypericin-mediated photodynamic therapy of human cancer cells. J Biol Chem 2003;278:52231-52239 (Pubitemid 38035811)
34. 2 checkpoint activation and inhibits apoptosis of human B cell lymphoma cells treated with etoposide. Apoptosis 2005;10:1111-1120
35. Sun Y, Sinicrope FA. Selective inhibitors of MEK1/ ERK44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells. Mol Cancer Ther 2005;4:51-59 (Pubitemid 40268066)
36. Navas TA, Nguyen AN, Hideshima T, et al. Inhibition of p38α MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X (L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 2006;20:1017-1027
37. Shi YY, Small GW, Orlowski RZ. Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer. Breast Cancer Res Treat 2006;100:33-47.
38. Kocanova S, Buytaert E, Matroule JY, et al. Induction of heme-oxygenase 1 requires the p38(MAPK) and PI3K pathways and suppresses apoptotic cell death following hypericin-mediated photodynamic therapy. Apoptosis 2007;12:731-741 (Pubitemid 46411467)
39. Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res 2005;15:11-18 (Pubitemid 41653958)
40. Maher P. p38 mitogen-activated protein kinase activation is required for fibroblast growth factor-2-stimulated cell proliferation but not differentiation. J Biol Chem 1999;274:17491-17498 (Pubitemid 129519094)
41. Crawley JB, Rawlinson L, Lali FV, Page TH, Saklatvala J, Foxwell BM. T cell proliferation in response to interleukins 2 and 7 requires p38MAP kinase activation. J Biol Chem 1997;272:15023-15027 (Pubitemid 27251779)
42. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 1996;271:20608-20616 (Pubitemid 26281839)
43. Casanovas O, Miro F, Estanyol JM, Itarte E, Agell N, Bachs O. Osmotic stress regulates the stability of cyclin D1 in a p38SAPK2-dependent manner. J Biol Chem 2000;275:35091-35097 (Pubitemid 30832524)
44. 2-M checkpoint after ultraviolet radiation requires p38 kinase. Nature 2001;411:102-107
45. Davidoff AM, Kerns BJ, Pence JC, Marks JR, Iglehart JD. p53 alterations in all stages of breast cancer. J Surg Oncol 1991;48:260-267
46. Fiscella M, Zhang H, Fan S, et al. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci U S A 1997;94:6048-6053 (Pubitemid 27270633)
47. Takekawa M, Adachi M, Nakahata A, et al. p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 2000;19:6517-6526
48. Li J, Yang Y, Peng Y, et al. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet 2002;31:133-134 (Pubitemid 34887608)
49. Hassapoglidou S, Diamandis EP, Sutherland DJ. Quantification of p53 protein in tumor cell lines, breast tissue extracts and serum with time-resolved immunofluorometry. Oncogene 1993;8:1501-1509 (Pubitemid 23189046)
50. Lee MR, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38α protein. Curr Med Chem 2005;12:2979-2994 (Pubitemid 41672487)